RESEARKA

However, this tension is tempered by the fact that Li 2025b evaluated a non-colchicine intervention; it does not constitute direct evidence against colchicine but rather highlights that inflammaging biomarker modulation is achievable under certain intervention conditions. Mathiesen 2025's REC1TE trial, once completed, is positioned to resolve whether colchicine's anti-inflammatory profile translates to measurable biomarker changes in a diabetes population. The current evidence landscape for colchicine and immune outcomes in inflammaging is therefore characterized by mechanistic rationale without confirmed human RCT data, and the boundary conditions for efficacy remain to be established.

Citation Support

• source_1 Mohammadnia 2025
• source_2 Li 2025
• source_3 Ammirati 2026
• source_4 Pascart 2026
• source_5 Broekhoven 2022